Prioritization of candidate cancer genes on chromosome 17q through reverse engineered transcriptional regulatory networks in medulloblastoma groups 3 and 4

• Group 3 and 4 MB present an intermediate to bad prognosis and high rates of metastasis. Amplification of (chromosome 17q) chr 17q is the most frequently observed genomic alteration in these patients and is coupled to a worsened prognosis. However, little is known about how or which genes on chr 17a contribute to the development of MB. Identification of such genes will greatly benefit from more integrative methods. Yet, functional association networks integrating multiple data types, a gold standard for such investigations, are largely missing for MB. In this project, we establish transcriptional regulatory networks of MB groups 3 and 4. Employing these networks, we were able to study the genomic events associated with MB groups 3 and 4 at a system wide level. Specifically, a focus lied on the identification of candidate cancer genes/modules on chr 17q through a network propagation strategy. Through these analyses, we have identified KIF18B as a putative, novel cancer gene of Group 4 MB, suggesting a promising potential for yet more integrative network-based studies.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medical Genetics (hsv//eng)

Nyckelord

medulloblastoma

chromosome 17q

cancer genes

transcriptional regulatory network

network propagation

Publikations- och innehållstyp

vet (ämneskategori)

ovr (ämneskategori)